The selected drugs predominantly target the PI3K/AKT and MAPK pathways, which are known to affect the response to RAF and MEK inhibitors in some melanoma cell lines and clinical samples [78], [79], [80], [81], [82]. This evidence concerns the gene AKT1 and melanoma.